Johanna Mylet - 21 Dec 2021 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: Chief Financial Officer
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 21 Dec 2021
Net transactions value: +$9,061
Form type: 4
Filing time: 22 Dec 2021, 15:53:09 UTC
Previous filing: 02 Nov 2021
Next filing: 01 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Options Exercise	$3,069	+2,616	+9.2%	$1.17	31,131	21 Dec 2021	Direct
transaction	PSTX	Common Stock	Options Exercise	$5,992	+3,100	+10%	$1.93	34,231	21 Dec 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Stock Option (Right to Buy)	Options Exercise	$0	-2,616	-100%	$0.000000^*	0	21 Dec 2021	Common Stock	2,616	$1.17	Direct	F1
transaction	PSTX	Stock Option (Right to Buy)	Options Exercise	$0	-3,100	-45%	$0.000000	3,816	21 Dec 2021	Common Stock	3,100	$1.93	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option is fully vested and exercisable.
F2	12.5% of the shares shares subject to the stock option vested and became exercisable on August 6, 2018, and the remaining shares vest in 42 equal monthly installments thereafter.